![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MED23 |
Gene summary for MED23 |
![]() |
Gene information | Species | Human | Gene symbol | MED23 | Gene ID | 9439 |
Gene name | mediator complex subunit 23 | |
Gene Alias | ARC130 | |
Cytomap | 6q23.2 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q05DL5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9439 | MED23 | HCC1_Meng | Human | Liver | HCC | 5.55e-09 | -3.35e-02 | 0.0246 |
9439 | MED23 | HCC2_Meng | Human | Liver | HCC | 1.68e-18 | 7.35e-02 | 0.0107 |
9439 | MED23 | HCC1 | Human | Liver | HCC | 1.19e-03 | 3.11e+00 | 0.5336 |
9439 | MED23 | HCC2 | Human | Liver | HCC | 2.38e-05 | 1.33e+00 | 0.5341 |
9439 | MED23 | S015 | Human | Liver | HCC | 1.34e-03 | 2.93e-01 | 0.2375 |
9439 | MED23 | S016 | Human | Liver | HCC | 2.07e-03 | 1.92e-01 | 0.2243 |
9439 | MED23 | S029 | Human | Liver | HCC | 9.08e-05 | 2.27e-01 | 0.2581 |
9439 | MED23 | HTA12-23-1 | Human | Pancreas | PDAC | 1.54e-02 | 5.19e-01 | 0.3405 |
9439 | MED23 | HTA12-26-1 | Human | Pancreas | PDAC | 1.29e-09 | 5.65e-01 | 0.3728 |
9439 | MED23 | HTA12-29-1 | Human | Pancreas | PDAC | 4.21e-19 | 4.15e-01 | 0.3722 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00063671 | Liver | HCC | transcription initiation from RNA polymerase II promoter | 52/7958 | 77/18723 | 7.87e-06 | 9.27e-05 | 52 |
GO:0006352 | Liver | HCC | DNA-templated transcription, initiation | 78/7958 | 130/18723 | 4.19e-05 | 4.11e-04 | 78 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MED23 | SNV | Missense_Mutation | novel | c.3989G>A | p.Arg1330Gln | p.R1330Q | Q9ULK4 | protein_coding | tolerated(0.07) | benign(0.079) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
MED23 | SNV | Missense_Mutation | rs766478634 | c.3982N>T | p.Arg1328Cys | p.R1328C | Q9ULK4 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MED23 | SNV | Missense_Mutation | c.3267C>A | p.Asn1089Lys | p.N1089K | Q9ULK4 | protein_coding | tolerated(0.51) | benign(0.251) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MED23 | SNV | Missense_Mutation | novel | c.586C>T | p.Leu196Phe | p.L196F | Q9ULK4 | protein_coding | tolerated(0.64) | benign(0.369) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MED23 | SNV | Missense_Mutation | novel | c.2626N>A | p.Gly876Arg | p.G876R | Q9ULK4 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
MED23 | SNV | Missense_Mutation | c.2171N>A | p.Pro724His | p.P724H | Q9ULK4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
MED23 | SNV | Missense_Mutation | c.1849N>T | p.Pro617Ser | p.P617S | Q9ULK4 | protein_coding | tolerated(0.19) | possibly_damaging(0.817) | TCGA-AP-A0LP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Hormone Therapy | megace | SD | |
MED23 | SNV | Missense_Mutation | novel | c.769N>T | p.Pro257Ser | p.P257S | Q9ULK4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MED23 | SNV | Missense_Mutation | rs148431716 | c.3724G>A | p.Glu1242Lys | p.E1242K | Q9ULK4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MED23 | SNV | Missense_Mutation | rs777436261 | c.2683G>A | p.Asp895Asn | p.D895N | Q9ULK4 | protein_coding | deleterious(0) | possibly_damaging(0.738) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |